This therapy is associated with enhanced CX3CL1 levels in human colon cancers, leading to the recruitment of non-classical monocytes to the vascular bed of the tumor, where they promote accumulation of neutrophils and immune suppression through IL-10 secretion (Jung et al., 2017). This evidence concerns the gene IL10 and colonic neoplasm.